[{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Durbin","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SIFI \/ Durbin","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Durbin"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"SIFI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Avanzanite Bioscience \/ SIFI","highestDevelopmentStatusID":"10","companyTruncated":"Avanzanite Bioscience \/ SIFI"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIFI \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"BioStem Technologies","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ BioStem Technologies","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biotech \/ BioStem Technologies"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Best Buy Medical Canada","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Undisclosed","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Best Buy Medical Canada","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Best Buy Medical Canada"},{"orgOrder":0,"company":"SIFI","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ University of California","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ University of California"}]

Find Clinical Drug Pipeline Developments & Deals for Polyhexanide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The collaboration aims to evaluate the Akantior (polihexanide), the first and only approved drug for the treatment of AK. It is being indicated for the treatment of Acanthamoeba Keratitis in US.

                          Product Name : Akantior

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 18, 2025

                          Lead Product(s) : Polyhexanide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : University of California

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The agreement aims for the distribution of revyve, an antimicrobial wound gel product line in infection management and wound healing.

                          Product Name : Revyve

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 11, 2025

                          Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                          Therapeutic Area : Podiatry

                          Highest Development Status : Approved FDF

                          Sponsor : Best Buy Medical Canada

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that got approval from european medicines agency for the treament of acanthamoeba keratitis.

                          Product Name : Akantior

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 16, 2024

                          Lead Product(s) : Polyhexanide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : BioStem Technologies will acquire exclusive US distribution rights for revyve from ProgenaCare Global.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 27, 2024

                          Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                          Therapeutic Area : Podiatry

                          Highest Development Status : Approved

                          Sponsor : BioStem Technologies

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.

                          Product Name : Revyve

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 14, 2024

                          Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The agreement aims for the distribution of revyve antimicrobial wound gel indicated for diabetic foot ulcers, in the Qatar wound care market.

                          Product Name : Revyve

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 28, 2024

                          Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                          Therapeutic Area : Podiatry

                          Highest Development Status : Approved

                          Sponsor : Qatar Datamation Systems

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that got approval from european medicines agency for the treament of acanthamoeba keratitis.

                          Product Name : Akantior

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 26, 2024

                          Lead Product(s) : Polyhexanide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.

                          Product Name : Akantior

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 22, 2024

                          Lead Product(s) : Polyhexanide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.

                          Product Name : Akantior

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 03, 2024

                          Lead Product(s) : Polyhexanide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Akantior® (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.

                          Product Name : Akantior

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 31, 2024

                          Lead Product(s) : Polyhexanide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank